Atrium Therapeutics Reports Third Quarter 2026 Financial Results
PR Newswire•12/11/2026•16:10 ET
0
Key Highlights
- ➤$50.0 million private placement extends Atrium’s cash runway through 2028
- ➤First patient dosed in ATR 1072’s Phase 1/2 PRKAG2 trial
- ➤$15.3 million Q3 collaboration revenue included a $15.0 million BMS milestone
- ➤$293.6 million pro-forma cash balance at September-end, including financing proceeds
- ➤Initial Corventis proof-of-concept data expected in the second half of 2027
Expert Statements
Kathleen Gallagher, President and Chief Executive Officer of Atrium Therapeutics
“The last eight months have marked many firsts for Atrium, building toward our transition to a clinical stage company with the initiation of Corventis, the first clinical trial ever to target the root cause of PRKAG2 syndrome”
Kathleen Gallagher, President and Chief Executive Officer of Atrium Therapeutics
“Our recent presentation of compelling nonclinical data continues to strengthen our belief that by addressing the underlying cause of PRKAG2 syndrome we can impact features of the disease. We remain focused on advancing our pipeline to deliver on the promise of precision cardiology for people impacted by genetic cardiomyopathies.”
Brendan Winslow, Chief Financial Officer of Atrium Therapeutics
“Our $50 million private placement with leading institutional investors extends our cash runway through 2028”
Brendan Winslow, Chief Financial Officer of Atrium Therapeutics
“With ~$290 million on our balance sheet, we are well positioned to deliver on our upcoming milestones.”
Atrium Therapeutics Reports Third Quarter 2026 Financial Results PR Newswire
-- First patient dosed with ATR 1072 in the Corventis™ Phase 1/2 clinical trial in PRKAG2 syndrome --
Get started
Create a free account to read the full story.